Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Clin Lymphoma Myeloma Leuk. 2014 Mar 5. pii: S2152-2650(14)00055-X. doi: 10.1016/j.clml.2014.02.013. [Epub ahead of print]

JAK2 V617F Mutation Status of 232 Patients Diagnosed With Chronic Myeloproliferative Neoplasms.

Author information

  • 1Division of Hematology, Department of Internal Medicine, Ataturk Training Hospital, Izmir, Turkey. Electronic address: bahriyepayzin@gmail.com.
  • 2Medical Genetics Laboratory, Ataturk Training Hospital, Izmir, Turkey.
  • 3Department of Hematology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.
  • 4Division of Hematology, Department of Internal Medicine, Ataturk Training Hospital, Izmir, Turkey.
  • 5Department of Pathology, Ataturk Training Hospital, Izmir, Turkey.
  • 6Department of Biochemistry, Ataturk Training Hospital, Izmir, Turkey.



The aim of this study was to investigate the presence of Janus kinase 2 (JAK2) V617F mutation in patients with break point cluster region-abelson negative chronic myeloproliferative neoplasms (CMPNs) in our center.


We compared patients with and without the mutation, and also patients with the homozygous and heterozygous mutation, in terms of different clinical and laboratory features.


The JAK2 V617F mutation was detected in 77 (95%), 88 (68%), and 17 (77%) of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) patients, respectively. Among JAK2 V617F-positive patients, the homozygous genotype was found in 39 (50.6%) of the 77 PV, 23 (26.1%) of the 88 ET, and 11 (64.7%) of the 17 PMF patients. Bleeding was seen in 14 (6%) of all patients. Upper gastrointestinal bleeds were the most common, seen in 11 patients. Out of 232 CMPN patients, 44 (19%) had thrombosis. The most common thrombotic event was transient ischemic attack (52%). Progression to myelofibrosis was seen in 1 (1.2%) PV and 3 (2.3%) ET patients, and progression to acute leukemia was seen in 2 (2.5%) PV and 3 (2.3%) ET patients. Three patients with PV (3.7%), 3 with ET (2.7%), and 5 with PMF (2.7%) died during follow-up.


JAK2 V617F mutation frequencies in our PV and ET patients were similar to those reported previously. JAK2 V617F mutation frequency in our PMF patients was greater than in previous reports. All of our PV patients with thrombosis and most of our ET patients with thrombosis (76.1%) were JAK2 V617F mutation-positive. This mutation seems to be correlated with thrombosis risk.

Copyright © 2014 Elsevier Inc. All rights reserved.


Essential thrombocythemia; JAK2 mutation; MPNs; Polycythemia vera; Primary myelofibrosis

[PubMed - as supplied by publisher]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk